Sphaera Pharma announces the successful completion of the first milestone of the MDR/ XDR TB project.
Sphaera Pharma today announced successful completion of the objectives of the first milestone as stipulated by the Wellcome Trust, UK. Earlier in 2015, Wellcome Trust had funded Sphaera Pharma and THSTI for a research program for treatment of MDR/ XDR TB. Sphaera Pharma had been awarded the Gates Grand Challenge Exploration award for the same project for early proof of concept studies. The company and anticipates an IND Filing for this project later in 2016. The therapy has a unique systems biology and a non anti-biotic based approach for treatment of MDR/ XDR TB afflicting the Indian sub continent.